Education
About Us
Working with TipRanks
Follow Us
Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
RESEARCH TOOLSreports
Total Valuation
Immuno-Biological Laboratories Co., Ltd. has a market cap or net worth of ¥4.87B. The enterprise value is ¥3.41B.
Market Cap¥4.87B
Enterprise Value¥3.41B
Share Statistics
Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,314,590
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immuno-Biological Laboratories Co., Ltd.’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 14.33%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)14.33%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee17.01M
Profits Per Employee4.37M
Employee Count57
Asset Turnover0.53
Inventory Turnover1.07
Valuation Ratios
The current PE Ratio of Immuno-Biological Laboratories Co., Ltd. is 17.95. Immuno-Biological Laboratories Co., Ltd.’s PEG ratio is -1.09.
PE Ratio17.95
PS Ratio0.00
PB Ratio3.51
Price to Fair Value2.95
Price to FCF143.27
Price to Operating Cash Flow143.27
PEG Ratio-1.09
Income Statement
In the last 12 months, Immuno-Biological Laboratories Co., Ltd. had revenue of 969.53M and earned 249.05M in profits. Earnings per share was 26.74.
Revenue969.53M
Gross Profit628.34M
Operating Income209.35M
Pretax Income209.86M
Net Income249.05M
EBITDA226.55M
Earnings Per Share (EPS)26.74
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Immuno-Biological Laboratories Co., Ltd. pays an annual dividend of ¥5, resulting in a dividend yield of ―
Dividend Per Share¥5
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change-2.50%
50-Day Moving Average482.70
200-Day Moving Average481.02
Relative Strength Index (RSI)58.72
Average Volume (3m)98.05K
Important Dates
Immuno-Biological Laboratories Co., Ltd. upcoming earnings date is Aug 1, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 1, 2025
Ex-Dividend DateMar 27, 2013
Financial Position
Immuno-Biological Laboratories Co., Ltd. as a current ratio of 4.94, with Debt / Equity ratio of 21.79%
Current Ratio4.94
Quick Ratio3.81
Debt to Market Cap0.05
Net Debt to EBITDA-2.74
Interest Coverage Ratio166.15
Taxes
In the past 12 months, Immuno-Biological Laboratories Co., Ltd. has paid -39.19M in taxes.
Income Tax-39.19M
Effective Tax Rate-0.19
Enterprise Valuation
Immuno-Biological Laboratories Co., Ltd. EV to EBITDA ratio is 16.99, with an EV/FCF ratio of 31.08.
EV to Sales3.97
EV to EBITDA16.99
EV to Free Cash Flow31.08
EV to Operating Cash Flow20.98
Balance Sheet
Immuno-Biological Laboratories Co., Ltd. has ¥753.00M in cash and marketable securities with ¥190.00M in debt, giving a net cash position of -¥563.00M billion.
Cash & Marketable Securities¥753.00M
Total Debt¥190.00M
Net Cash-¥563.00M
Net Cash Per Share-¥60.44
Tangible Book Value Per Share¥162.60
Margins
Gross margin is 66.28%, with operating margin of 21.59%, and net profit margin of 25.69%.
Gross Margin66.28%
Operating Margin21.59%
Pretax Margin21.65%
Net Profit Margin25.69%
EBITDA Margin23.37%
EBIT Margin21.78%
Analyst Forecast
The average price target for Immuno-Biological Laboratories Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast18.71%
EPS Growth Forecast33.40%